{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T15:43:30Z","timestamp":1765727010599,"version":"3.48.0"},"reference-count":28,"publisher":"BMJ","issue":"7","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2016,6,14]]},"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The emergence of multidrug resistant (MDR) Gram-negative bacteria (GNB), including carbapenemase-producing strains, has become a major therapeutic challenge. These MDR isolates are often involved in complicated urinary tract infection (cUTI), and are associated with poor clinical outcomes. The study has been designed to gain insight into the epidemiology, clinical management, outcome and healthcare cost of patients with cUTI, especially in countries with high prevalence of MDR GNB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>\n                      This multinational and multicentre observational, retrospective study will identify cases from 1 January 2013 to 31 December 2014 in order to collect data on patients with cUTI as a cause of hospital admission, and patients who develop cUTI during their hospital stay. The primary end point will be treatment failure defined as the presence of any of the following criteria: (1) signs or symptoms of cUTI present at diagnosis that have not improved by days 5\u20137 with appropriate antibiotic therapy, (2) new cUTI-related symptoms that have developed within 30\u2005days of diagnosis, (3) urine culture taken within 30\u2005days of diagnosis, either during or after completion of therapy, that grows \u226510\n                      <jats:sup>4<\/jats:sup>\n                      colony-forming unit\/mL of the original pathogen and (4) death irrespective of cause within 30\u2005days of the cUTI diagnosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Sample size<\/jats:title>\n                    <jats:p>1000 patients afford a power of 0.83 (\u03b1=0.05) to detect an absolute difference of 10% in the treatment failure rate between MDR bacteria and other pathogens. This should allow for the introduction of about 20 independent risk factors (or their interaction) in a logistic regression model looking at risk factors for failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Approval will be sought from all relevant Research Ethics Committees. Publication of this study will be considered as a joint publication by the participating investigator leads, and will follow the recommendations of the International Committee of Medical Journal Editors (ICMJE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>NCT02641015; Pre-results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2016-011500","type":"journal-article","created":{"date-parts":[[2016,7,29]],"date-time":"2016-07-29T21:39:44Z","timestamp":1469828384000},"page":"e011500","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Retrospective observational study to assess the clinical management and outcomes of hospitalised patients with complicated urinary tract infection in countries with high prevalence of multidrug resistant Gram-negative bacteria (RESCUING)"],"prefix":"10.1136","volume":"6","author":[{"given":"Evelyn","family":"Shaw","sequence":"first","affiliation":[{"name":"Departament of Infectious Diseases, Institut Catal\u00e0 de la Salut-Hospital Universitari de Bellvitge (ICS-HUB)-IDIBELL, Barcelona, Spain"},{"name":"Spanish network for research in Infectious Diseases (REIPI RD12\/0012), Instituto de Salud Carlos III, Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibironke","family":"Addy","sequence":"additional","affiliation":[{"name":"AiCuris Anti-infective Cures GmbH, Wuppertal, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Stoddart","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Southmead Hospital, North Bristol NHS Trust, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Vank","sequence":"additional","affiliation":[{"name":"AiCuris Anti-infective Cures GmbH, Wuppertal, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Grier","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Southmead Hospital, North Bristol NHS Trust, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irith","family":"Wiegand","sequence":"additional","affiliation":[{"name":"AiCuris Anti-infective Cures GmbH, Wuppertal, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard","family":"Leibovici","sequence":"additional","affiliation":[{"name":"Department of Medicine E, Beilinson Hospital, Rabin Medical Center, Petah-Tiqva, Israel"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University, Petah Tikva, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noa","family":"Eliakim-Raz","sequence":"additional","affiliation":[{"name":"Department of Medicine E, Beilinson Hospital, Rabin Medical Center, Petah-Tiqva, Israel"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University, Petah Tikva, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Vallejo-Torres","sequence":"additional","affiliation":[{"name":"Department of Applied Health Research, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Morris","sequence":"additional","affiliation":[{"name":"Department of Applied Health Research, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alasdair","family":"MacGowan","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Southmead Hospital, North Bristol NHS Trust, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Carratal\u00e0","sequence":"additional","affiliation":[{"name":"Departament of Infectious Diseases, Institut Catal\u00e0 de la Salut-Hospital Universitari de Bellvitge (ICS-HUB)-IDIBELL, Barcelona, Spain"},{"name":"Spanish network for research in Infectious Diseases (REIPI RD12\/0012), Instituto de Salud Carlos III, Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miquel","family":"Pujol","sequence":"additional","affiliation":[{"name":"Departament of Infectious Diseases, Institut Catal\u00e0 de la Salut-Hospital Universitari de Bellvitge (ICS-HUB)-IDIBELL, Barcelona, Spain"},{"name":"Spanish network for research in Infectious Diseases (REIPI RD12\/0012), Instituto de Salud Carlos III, Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2016,7,29]]},"reference":[{"key":"2025121407393141000_6.7.e011500.1","unstructured":"Annual Report of the Chief Medical Officer, Volume Two, 2011, Infections and the rise of antimicrobial resistance (published on March 2013). https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/138331\/CMO_Annual_Report_Volume_2_2011.pdf"},{"key":"2025121407393141000_6.7.e011500.2","unstructured":"UK Five Year Antimicrobial Resistance Strategy 2013\u20132018, September 2013. https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/244058\/20130902_UK_5_year_AMR_strategy.pdf"},{"key":"2025121407393141000_6.7.e011500.3","unstructured":"European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2013. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC, 2014. http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/antimicrobial-resistance-surveillance-europe-2013.pdf"},{"key":"2025121407393141000_6.7.e011500.4","first-page":"3590","article-title":"The European Union Summary Report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2012","volume":"12","author":"EFSA (European Food Safety Authority) and ECDC (European Centre for Disease Prevention and Control)","year":"2014","journal-title":"EFSA J"},{"key":"2025121407393141000_6.7.e011500.5","doi-asserted-by":"publisher","DOI":"10.3390\/ph6111335"},{"key":"2025121407393141000_6.7.e011500.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2012.05.024"},{"key":"2025121407393141000_6.7.e011500.7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"2025121407393141000_6.7.e011500.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1684-1182(10)60031-X"},{"key":"2025121407393141000_6.7.e011500.9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ijantimicag.2013.07.018","article-title":"Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli in patients with cancer","volume":"42","author":"Ha","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"2025121407393141000_6.7.e011500.10","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/QCO.0000000000000038","article-title":"Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact","volume":"27","author":"Trecarichi","year":"2014","journal-title":"Curr Opin Infect Dis"},{"key":"2025121407393141000_6.7.e011500.11","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-0087"},{"key":"2025121407393141000_6.7.e011500.12","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit688"},{"key":"2025121407393141000_6.7.e011500.13","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-013-0315-7"},{"key":"2025121407393141000_6.7.e011500.14","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199753040-00004"},{"key":"2025121407393141000_6.7.e011500.15","unstructured":"Grabe M , Bartoletti R , Bjerklund-Johansen TE , et al . Guidelines on urological infections. Eur Assoc Urol 2014. http:\/\/uroweb.org\/wp-content\/uploads\/19-Urological-infections_LR.pdf"},{"key":"2025121407393141000_6.7.e011500.16","doi-asserted-by":"publisher","DOI":"10.1067\/mda.2003.7"},{"key":"2025121407393141000_6.7.e011500.17","unstructured":"European Centre for Disease prevention and Control. Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals. Stockholm: ECDC, 2013. http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/healthcare-associated-infections-antimicrobial-use-PPS.pdf"},{"key":"2025121407393141000_6.7.e011500.18","unstructured":"International Classification of Diseases ICD-9 Data. http:\/\/icd9data.com\/2015\/volume1\/580\u2013629\/default.htm"},{"key":"2025121407393141000_6.7.e011500.19","unstructured":"International Statistical Classification of diseases and related Health Problems 10th Revision. ICD-10. Version 2015. http:\/\/apps.who.int\/classifications\/icd10\/browse\/2015\/en"},{"key":"2025121407393141000_6.7.e011500.20","unstructured":"Complicated Urinary Tract Infections: Developing Drugs for Treatment. Guidance for Industry. U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER), 2015. http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/ucm070981.pdf"},{"key":"2025121407393141000_6.7.e011500.21","unstructured":"European Medicines Agency (EMA). Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. December 2011. Committee for Medical Products for Human Use (CHMP). http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003417.pdf"},{"key":"2025121407393141000_6.7.e011500.22","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2012.73"},{"key":"2025121407393141000_6.7.e011500.23","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"2025121407393141000_6.7.e011500.24","unstructured":"Karnofsky DA , Burchenal JH . The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, ed . Evaluation of chemotherapeutic agents. New York: Columbia University Press, 1949:191\u2013205."},{"key":"2025121407393141000_6.7.e011500.25","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.clinthera.2015.06.013","article-title":"Assessment of outpatient and inpatient antibiotic treatment patterns and health care costs of patients with complicated urinary tract infections","volume":"37","author":"Turner","year":"2015","journal-title":"Clin Ther"},{"key":"2025121407393141000_6.7.e011500.26","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2010.11.2217"},{"key":"2025121407393141000_6.7.e011500.27","doi-asserted-by":"publisher","DOI":"10.1258\/1355819042250249"},{"key":"2025121407393141000_6.7.e011500.28","unstructured":"Directive 95\/46\/EC of the European Parliament and of the Council of 24 October 1995 on the protection of individuals with regard to the processing of personal data and on the free movement of such data. Official Journal L 281, 23\/11\/1995 P. 0031\u20140050EU."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2016-011500","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T15:39:40Z","timestamp":1765726780000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2016-011500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":28,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2016,7,29]]},"published-print":{"date-parts":[[2016,7]]}},"alternative-id":["10.1136\/bmjopen-2016-011500"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2016-011500","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2016,7]]}}}